Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Myasthenia Gravis
Nils Erik Gilhus
New England Journal of Medicine (2016) Vol. 375, Iss. 26, pp. 2570-2581
Closed Access | Times Cited: 793

Showing 1-25 of 793 citing articles:

Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue
Anand Padmanabhan, Laura Connelly‐Smith, Nicole A. Aqui, et al.
Journal of Clinical Apheresis (2019) Vol. 34, Iss. 3, pp. 171-354
Closed Access | Times Cited: 2092
Myasthenia gravis
Nils Erik Gilhus, Socrates J. Tzartos, Amelia Evoli, et al.
Nature Reviews Disease Primers (2019) Vol. 5, Iss. 1
Closed Access | Times Cited: 600
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial
James F. Howard, Vera Bril, Tuan Vu, et al.
The Lancet Neurology (2021) Vol. 20, Iss. 7, pp. 526-536
Open Access | Times Cited: 402
Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue
Laura Connelly‐Smith, Caroline R. Alquist, Nicole A. Aqui, et al.
Journal of Clinical Apheresis (2023) Vol. 38, Iss. 2, pp. 77-278
Closed Access | Times Cited: 284
Myasthenia Gravis: Epidemiology, Pathophysiology and Clinical Manifestations
Laura Dresser, Richard Wlodarski, Kourosh Rezania, et al.
Journal of Clinical Medicine (2021) Vol. 10, Iss. 11, pp. 2235-2235
Open Access | Times Cited: 273
Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis
James F. Howard, Vera Bril, Ted M. Burns, et al.
Neurology (2019) Vol. 92, Iss. 23
Open Access | Times Cited: 226
Treatment of Myasthenia Gravis
Constantine Farmakidis, Mamatha Pasnoor, Mazen M. Dimachkie, et al.
Neurologic Clinics (2018) Vol. 36, Iss. 2, pp. 311-337
Open Access | Times Cited: 191
Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial
Gil I. Wolfe, Henry J. Kaminski, Inmaculada Aban, et al.
The Lancet Neurology (2019) Vol. 18, Iss. 3, pp. 259-268
Open Access | Times Cited: 179
Autoimmune Encephalitis Misdiagnosis in Adults
Eoin P. Flanagan, Michael D. Geschwind, A. Sebastian López‐Chiriboga, et al.
JAMA Neurology (2022) Vol. 80, Iss. 1, pp. 30-30
Open Access | Times Cited: 174
T Follicular Helper Cells in Autoimmune Disorders
Noémie Gensous, Manon Charrier, Dorothée Duluc, et al.
Frontiers in Immunology (2018) Vol. 9
Open Access | Times Cited: 170
Myasthenia Gravis Associated With SARS-CoV-2 Infection
Domenico A. Restivo, Diego Centonze, Alessandro Alesina, et al.
Annals of Internal Medicine (2020) Vol. 173, Iss. 12, pp. 1027-1028
Open Access | Times Cited: 166
Generalized Myasthenia Gravis
Michael K. Hehir, Nicholas J. Silvestri
Neurologic Clinics (2018) Vol. 36, Iss. 2, pp. 253-260
Closed Access | Times Cited: 162
Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis
James F. Howard, Richard J. Nowak, Gil I. Wolfe, et al.
JAMA Neurology (2020) Vol. 77, Iss. 5, pp. 582-582
Open Access | Times Cited: 153
The immunosuppressive activity of artemisinin‐type drugs towards inflammatory and autoimmune diseases
Thomas Efferth, Franz Oesch
Medicinal Research Reviews (2021) Vol. 41, Iss. 6, pp. 3023-3061
Closed Access | Times Cited: 136
Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study
Volkan Granit, Michael Benatar, Metin Kurtoğlu, et al.
The Lancet Neurology (2023) Vol. 22, Iss. 7, pp. 578-590
Closed Access | Times Cited: 117
Virtual Reality for Neurorehabilitation and Cognitive Enhancement
Данко Георгиев, Iva Georgieva, Zhengya Gong, et al.
Brain Sciences (2021) Vol. 11, Iss. 2, pp. 221-221
Open Access | Times Cited: 116
Plasma exchange in the intensive care unit: a narrative review
Philippe R. Bauer, Marlies Ostermann, Lene Russell, et al.
Intensive Care Medicine (2022) Vol. 48, Iss. 10, pp. 1382-1396
Open Access | Times Cited: 84
Identification of genetic risk loci and prioritization of genes and pathways for myasthenia gravis: a genome-wide association study
Ruth Chia, Sara Sáez-Atiénzar, Natalie A. Murphy, et al.
Proceedings of the National Academy of Sciences (2022) Vol. 119, Iss. 5
Open Access | Times Cited: 80
Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension
Andreas Meisel, Djillali Annane, Tuan Vu, et al.
Journal of Neurology (2023) Vol. 270, Iss. 8, pp. 3862-3875
Open Access | Times Cited: 55
Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis
James F. Howard, Vera Bril, Tuan Vu, et al.
Frontiers in Neurology (2024) Vol. 14
Open Access | Times Cited: 28
Generalized myasthenia gravis with acetylcholine receptor antibodies: A guidance for treatment
Nils Erik Gilhus, Henning Andersen, Linda Kahr Andersen, et al.
European Journal of Neurology (2024) Vol. 31, Iss. 5
Open Access | Times Cited: 23
B cell lineage reconstitution underlies CAR-T cell therapeutic efficacy in patients with refractory myasthenia gravis
Dai‐Shi Tian, Chuan Qin, Minghao Dong, et al.
EMBO Molecular Medicine (2024) Vol. 16, Iss. 4, pp. 966-987
Open Access | Times Cited: 22
Treatment of concomitant myasthenia gravis and Lambert-Eaton myasthenic syndrome with autologous CD19-targeted CAR T cells
Jeremias Motte, Melissa Sgodzai, Christiane Schneider‐Gold, et al.
Neuron (2024) Vol. 112, Iss. 11, pp. 1757-1763.e2
Open Access | Times Cited: 19
Short-term and long-term prognoses in AChR-Ab positive very-late-onset myasthenia gravis patients
Nairong Xie, Qing Liu, Qi Wen, et al.
Therapeutic Advances in Neurological Disorders (2025) Vol. 18
Open Access | Times Cited: 2
Application of efgartigimod in Chinese patients with myasthenia gravis: a single-center real-world prospective study
Geke Zhu, Han Zhou, Wanying Wang, et al.
Therapeutic Advances in Neurological Disorders (2025) Vol. 18
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top